CSL Nabs First ‘Direct Access’ Funding Agreement In France For Its Gene Therapy

Hemgenix (etranacogene dezaparvovec), a one-time gene therapy from CSL Behring that has a US list price of $3.5m, has been granted full reimbursement for up to a year in France through a an exceptional access scheme launched two years ago.

France’s direct access program was introduced under a social security financing law that was passed in December 2021 (LFSS 2022). On 13 December, Hemgenix became the first medicine to receive funding through the initiative